The number of people living with HIV/AIDS worldwide has reached 34 million.
But despite the importance of developing a vaccine for the disease, research groups and small biopharma companies are finding challenges in obtaining the amount of funding required to conduct effective research and clinical trials.
Robert McNally, CEO of GeoVax, an Atlanta-based company that is working on vaccines to fight and prevent HIV, explores this funding question in a new GHN Commentary.
“Why has the HIV/AIDS crisis diminished in the public consciousness, domestically and elsewhere, despite the continued high cost of present treatment regimens?’’ McNally writes.
Here’s a link to McNally’s Commentary.
Georgia Health News welcomes Commentary submissions. If you would like to propose a Commentary piece for Georgia Health News, please e-mail Andy Miller, editor of GHN, at amiller@georgiahealthnews.com
Sign up for our free email alerts and follow us on Facebook and on Twitter @gahealthnews.
Help us fulfill our nonprofit mission with a tax-deductible donation!
Andy Miller
Andy Miller is editor and CEO of Georgia Health News
Health care and the election
Nov 2, 2020 0
Lawsuit over tainted water
Aug 8, 2020 1
Stopping the COVID spread
Jul 24, 2020 0
No comments so far.
Be first to leave comment below.